Reasons why midostaurin is contraindicated and what patients should know

Midostaurin (Midostaurin) is a multi-target tyrosine kinase inhibitor mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML) and systemic mastocytosis (SM). Although the drug has been approved for marketing in many countries around the world and has shown good efficacy in clinical applications, it may be banned or restricted in use in certain specific circumstances.

First, midostaurin may be limited due to serious adverse effects. Common side effects include nausea, vomiting, diarrhea, fatigue and rash, and some patients may experience cardiotoxicity, such as QT interval prolongation, arrhythmia, and even serious cardiovascular events. Therefore, patients with underlying heart disease or taking other drugs that prolong the QT interval should use it with caution.

Second, midostaurin may not be suitable for use in patients with impaired hepatic function. The drug is mainly metabolized in the liver. Once liver function is abnormal, the clearance rate of the drug may be reduced, leading to drug accumulation and increasing the risk of toxicity. Doctors usually monitor patients' liver function and may need to adjust the dose or stop the drug if significant abnormalities are found.

In addition, midostaurin may interact with certain drugs, especiallystrong inhibitors or inducers of CYP3A4, such as certain antibiotics, anti-epileptic drugs and steroids. These drugs may affect the metabolism of midostaurin, resulting in decreased efficacy or increased side effects. Therefore, when combining medications, doctors need to weigh the risks and may choose alternative treatment options.

Pregnant and nursing women are generally advised not to take midostaurin because of the potential for adverse effects on the fetus or infant. Animal experiments show that the drug may cause abnormal fetal development, so a pregnancy test must be performed before taking the drug and effective contraceptive measures must be taken.

Reference materials:https://medlineplus.gov/druginfo/meds/a617033.html